This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

HomeBrowseAboutFAQs
Log In
Sign Up
Mood Disorder

Anti-inflmmation Treatment in Mood Disorder and Deep Learning Prediction Model

Sponsored by Taipei Veterans General Hospital, Taiwan

About this trial

Last updated 4 years ago

Study ID

109-2314-B-010 -050 -MY3

Status

Unknown status

Type

Interventional

Phase

Phase 4

Placebo

No

Accepting

18-75 Years
20 to 65 Years
All
All

Not accepting

Not accepting
Healthy Volunteers

Trial Timing

Ended 2 years ago

What is this trial about?

This three-year study will enroll 180 patients with mood disorders (90 patients with major depressive disorder and 90 patients with bipolar disorder) and high pro-inflammatory cytokine levels. They will be randomly assigned to three groups of aspirin, statin and control groups for 12 weeks according to the disease group. The first aim of the study is to compare the efficacy of aspirin and statin in mood disorders. The second aim is to establish a gene-immuno-brain imaging treatment prediction model by deep learning technology, using pretreatment cytokines, neurocognitive function, brain structural/functional connectivity, and telomere length as the predictors.

What are the participation requirements?

Yes

Inclusion Criteria

1. Age between 20 to 65 years old.

2. The baseline pro-inflammatory cytokines level: soluble IL6 receptor (sIL-6)>35,000pg/ml, or CRP>1,500ng/ml, or sTNF-R1>1,000pg/ml.

3. Maintain psychiatric medication for more than three months.

4. Voluntary patients and controls with signed informed consent proved by institutional review board (IRB).

No

Exclusion Criteria

1. Patients have used aspirin, statin previously .

2. Patients have gastrointestinal disease, history of gastrointestinal bleeding, hematology coagulation disease, sever liver and renal disease.

3. Patients with schizophrenia, organic brain diseases, mental retardation.

4. Patients with symptoms of substance abuse/dependence (except nicotine dependence) within 3 months.

5. Patients with autoimmune, acute infection and critical medical illnesses .

6. Patients who cannot cooperate the study protocol.

Locations

Location

Status

Recruiting